[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-covid-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-covid-syndrome":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,82,114,141,163,195,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":18,"phases":4,"briefSummary":19,"conditions":20,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":41,"locationsCount":44},"100618493","expanded-access-use-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-chronic-fatigue-of-post-covid-condition-100618493",false,"NCT07332338","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)\n* Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters","ALL","18 Years","EXPANDED_ACCESS","REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.",[21,22,23,24,25,26,27],"Post-COVID-19 Condition","Post-COVID Condition","Post-COVID Syndrome","Long COVID","Chronic Fatigue","Chronic Fatigue Symptoms","Fatigue Post Viral",[24,29,30,31,32,33,34,35],"Post-COVID syndrome","Post-COVID condition","Umbilical cord blood","REGENECYTE","Post-COVID fatigue","Chronic fatigue symptoms","Fatigue post viral","AVAILABLE","2026-03-18",{"date":39,"type":40},"2026-03-23","ACTUAL",{"name":42,"class":43},"StemCyte, Inc.","INDUSTRY",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100522430","improving-post-covid-19-syndrome-with-hyperbaric-oxygen-treatments-100522430","NCT06082518","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments (PCS-HBOT Study)","PCS-HBOT","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Officially diagnosed with post COVID-19 condition by a healthcare practitioner\n3. At least three months since SARS-CoV-2 infection\n4. Symptoms that persist more than 12 weeks:\n\n   * Chronic fatigue (must include) along with one of the following symptoms:\n   * Difficulty thinking or problem solving ('brain fog')\n   * Stress or anxiety\n\nExclusion Criteria:\n\n1. Contraindications\u002Fmedically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)\n2. Patients with cognitive difficulties and\u002For mental retardation before COVID diagnosis\n3. History of traumatic brain injury\n4. Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)\n5. Known pregnancy or planning a pregnancy in women of childbearing age",{"count":54,"type":55},40,"ESTIMATED","INTERVENTIONAL",[58],"NA","Over 500 million people have been infected with COVID-19, and to date, more than 6 million people have died. Many individuals who have recovered from COVID-19 continue to experience symptoms even after they have been \"cured\" of the disease. This condition is known as post COVID-19 condition, which can have serious health consequences. A common symptom among these individuals is chronic fatigue, characterized by persistent tiredness or lack of energy. This study aims to explore a novel treatment for symptoms of post COVID-19 condition, known as hyperbaric oxygen therapy. This approach has shown promise in helping people with post COVID-19 conditions and treating some other causes of fatigue.\n\nHyperbaric oxygen therapy involves placing patients in a small chamber where they receive high oxygen gas levels. However, this treatment is expensive and time-consuming, and it is unclear if this treatment can be effectively assessed in a large-scale research study. This small study will help us decide if conducting a large research study is feasible. The investigators aim to assess if hyperbaric oxygen therapy can improve symptoms of post COVID-19 condition, such as fatigue.",[61,62,23,63,64,65],"Post COVID-19 Condition","Post-COVID-19 Syndrome","COVID-19","Fatigue","Fatigue Syndrome, Chronic",[67,68,61,64,69,63],"Hyperbaric Oxygen Therapy","HBOT","Severe Acute Respiratory Syndrome-CoV-2","RECRUITING","2026-03-12",{"date":73,"type":40},"2026-03-16",{"date":75,"type":40},"2024-01-02",{"date":77,"type":55},"2027-05",{"name":79,"class":80},"Sunnybrook Health Sciences Centre","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":56,"phases":93,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":81},"100617246","phase-2-immunoadsorption-in-autoimmune-long-covid-100617246","NCT07316127","Immunoadsorption in Autoimmune Long COVID","A Placebo-Controlled, Double-Blind, Randomized Trial Phase I-II With Immunoadsorption in Autoimmune Long COVID","TURNLongCOVID","Inclusion Criteria:\n\n* Long COVID based on the WHO-criteria\n* PEM according to the DSQ-PEM\n* BELL's functionality score 20-70%\n* Good health prior to the long COVID diagnosis (WHO performance score 0)\n\nExclusion Criteria:\n\n* Medical history of clinically significant respiratory- or cardiovascular disease\n* Prior interventional cardiac procedure within 3 months prior to randomization\n* Active immunosuppresive treatment for systemic autoimmune disorders\n* Diabetes type 1\n* Solid organ malignancy in the last 5 years\n* Active psychiatric disorder currently under treatment by a psychiatrist\n* BMI \\> 35\n* Pre-existing fatigue\n* Poor performance score prior to the long COVID diagnosis (WHO performance \\>0)\n* Pregnancy or breastfeeding","65 Years",{"count":92,"type":55},70,[94],"PHASE2","Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.\n\nThis study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months.\n\nThis research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.",[24,97,98,99],"Long COVID Syndrome","Long COVID-19 Syndrome","Post COVID Syndrome",[101,102,103,104],"immunoadsorption","long COVID","post COVID","plasmapheresis","2025-12-18",{"date":107,"type":40},"2026-01-05",{"date":109,"type":55},"2026-01-01",{"date":111,"type":55},"2028-03-12",{"name":113,"class":80},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":56,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100616956","whole-body-electrostimulation-for-functional-recovery-in-post-covid-syndrome-100616956","NCT07312357","Whole-Body Electrostimulation for Functional Recovery in Post-COVID Syndrome","Electrostimulation Suit as a Therapeutic Tool in Post-COVID Syndrome: Effects on Physical and Functional Status. A Randomized Controlled Trial","WB-EMS PostCOV","Inclusion Criteria:Adults aged 18 years or older.\n\nDiagnosis of post-COVID syndrome (long COVID), with persistent symptoms following SARS-CoV-2 infection.\n\nPresence of fatigue and\u002For functional limitations associated with post-COVID syndrome.\n\nAbility to understand the study procedures and provide written informed consent.\n\nAbility to participate in the intervention and assessments according to the study protocol.\n\n\\-\n\nExclusion Criteria:\n\nParticipation in other structured physical exercise or rehabilitation programs during the study period.\n\nPresence of severe cardiovascular disease or uncontrolled medical conditions that contraindicate physical activity or electrostimulation.\n\nNeurological disorders or severe neuromuscular diseases.\n\nUse of anabolic drugs or medications that may interfere with muscle function.\n\nPregnancy.\n\nEpilepsy.\n\nActive skin lesions or dermatological conditions in areas where electrodes are applied.\n\nRecent oncological surgery.\n\nAcute venous thrombosis.\n\nPresence of cardiac pacemakers or implanted electronic or conductive medical devices.\n\nAny clinical deterioration or condition that, in the opinion of the investigators, would make participation unsafe.\n\n\\-","70 Years",{"count":124,"type":55},30,[58],"Post-COVID syndrome is a condition that affects some people after recovering from the acute phase of COVID-19. Common symptoms include persistent fatigue, reduced physical capacity, and difficulties performing everyday activities, which can significantly impact quality of life and independence. At present, there is limited scientific evidence on effective rehabilitation strategies for this population.\n\nThe purpose of this study is to evaluate whether the use of a whole-body electrostimulation suit can improve fatigue, physical performance, and functional independence in people with post-COVID syndrome. Whole-body electrostimulation is a non-pharmacological technique that uses low-frequency electrical impulses to activate multiple muscle groups simultaneously and has shown potential benefits in other clinical populations.\n\nThis is a randomized, double-blind, controlled pilot clinical trial. Participants will be randomly assigned to either an experimental group, which will receive active whole-body electrostimulation during functional activities, or a control group, which will follow the same sessions using the electrostimulation suit with minimal stimulation (placebo condition). Neither participants nor outcome assessors will know which group each participant belongs to.\n\nThe intervention will consist of 12 supervised sessions conducted once per week. Outcomes will be assessed before and after the intervention, with an additional follow-up assessment three months later. The main outcomes include fatigue levels, functional capacity, physical performance, and independence in activities of daily living. Safety and tolerance to the intervention will be monitored throughout the study.\n\nThe results of this study may help to determine the feasibility and potential effectiveness of whole-body electrostimulation as a rehabilitation tool for people with post-COVID syndrome and provide preliminary data for future larger-scale clinical trials.",[128,99,129,130],"Post COVID Syndrome Long Covid","Long COVID Fatigue","Long Covid","NOT_YET_RECRUITING","2025-12-16",{"date":134,"type":40},"2025-12-31",{"date":136,"type":55},"2026-03",{"date":138,"type":55},"2026-12",{"name":140,"class":80},"Universidad Rey Juan Carlos",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":148,"targetDuration":4,"studyType":56,"phases":150,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100607117","phase-3-a-study-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-post-covid-condition-100607117","NCT07184385","A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition","A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters",{"count":149,"type":55},60,[151],"PHASE3","REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.",[24,21,23,22],[30,29,24,32,33,31],"2025-09-18",{"date":157,"type":40},"2025-09-23",{"date":159,"type":55},"2026-03-31",{"date":161,"type":55},"2027-09-30",{"name":42,"class":43},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":56,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":81},"100594012","effects-of-hydrotherapy-during-post-covid-19-rehabilitation-100594012","NCT07013903","Effects of Hydrotherapy During Post-COVID-19 Rehabilitation","Effects of Kneipp Hydrotherapy During Inpatient Post-Covid-19 Rehabilitation: A Randomized Controlled Trial","HydroCoVital A","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Referred to the reference center for Post-COVID rehabilitation\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":172,"type":55},50,[58],"This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.",[176,177,99,22],"Post-COVID \u002F Long-COVID","POST-Covid 19",[179,180,181,24,182,183,184,185,30,186],"rehabilitation","therapy","Post-COVID","intervention","hydrotherapy","Kneipp","balneotherapy","quality of life","2025-08-21",{"date":189,"type":40},"2025-08-28",{"date":187,"type":40},{"date":192,"type":55},"2027-10-31",{"name":194,"class":80},"Schön Klinik Berchtesgadener Land",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":56,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":81},"100528085","pursuing-reduction-in-fatigue-after-covid-19-via-exercise-and-rehabilitation-prefacer-a-randomized-feasibility-trial-100528085","NCT06156176","Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial","PREFACER","Inclusion Criteria:\n\n* Adults of at least 18 years of age\n* Able to provide informed consent\n* Can speak and understand English\n* Documented history of SARS-CoV-2 infection (positive PCR\u002Fantigen test during acute illness or clinical diagnosis by physician during or after the acute illness)\n* Fatigue symptoms within 3 months of COVID-19 infection, lasting at least 2 months\n* Fatigue symptoms cannot be explained by an alternative diagnosis\n* Fatigue symptoms may be new onset following initial recovery from an acute COVID-19 infection or persist from the initial illness\n* Fatigue symptoms may have an episodic nature, fluctuate or relapse over time\n* Minimal functional capability: able to walk 10-15 minutes and be recovered within 30-60 minutes or without significant post-exertional malaise (PEM)\n* Has applicable technology to access Microsoft Teams and Webex (i.e., computer, laptop, tablet)\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\n* Pre-existing physical, cognitive, and\u002For mental health conditions that make exercise contraindicated, consent unattainable, or that cause symptoms similar to those seen in post COVID-19 (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome) that could affect data\n* Inability to follow study procedures\n* Pregnant and\u002For breastfeeding\n* Received investigational agents as part of a separate study within 30 days of the screening visit\n* Has any type of metal bodily implant in head or heart (i.e., pins, plates, pacemakers)\n* Current participation in other studies related to COVID-19, exercise, and\u002For fatigue interventions OR participation within 30 days of the screening visit",{"count":149,"type":55},[58],"Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants will be recruited, randomly assigned to the COVIDEx program or standard of care (SoC) and followed for 24 weeks.",[206,207,62,23,64,61,22],"Long-COVID","Long COVID-19","2025-07-29",{"date":210,"type":40},"2025-08-01",{"date":212,"type":40},"2025-04-01",{"date":214,"type":55},"2026-04-01",{"name":216,"class":80},"Lawson Research Institute of St. Joseph's",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":227,"studyType":228,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":81},"100501154","retrospective-and-prospective-cohort-of-patients-entering-the-multidisciplinary-management-of-post-covid-syndromes-100501154","NCT05805566","Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes","Post-Covid Syndrome Cohort","SyPoCo","Inclusion Criteria:\n\nAll patients who have joined the Epsilon care pathway since its opening in February 2022, i.e.:\n\n* Patients with post-Covid syndrome referred to the Epsilon sector from the city medicine:\n* Patient with documented SARS-Cov2 pneumonia\n* With persistent and severe symptoms beyond 4 weeks or complex or disabling symptoms beyond 3 months\n* Patient over 18 years old.\n\nPost-hospital sector:\n\n* Patient with documented SARS-Cov2 pneumonia\n* Hospitalized for oxygen therapy (at least 48h)\n* Not having a referring pulmonologist\n* Not institutionalized\n* With a life expectancy of more than 6 months.\n\nExclusion Criteria:\n\n* Patient refusing that this data to be used for research purposes (objection form).\n* Patient with untreated comorbidities",{"count":226,"type":55},750,"1 Year","OBSERVATIONAL","SARS-CoV2 pneumonia has been a global public health emergency since 2020. The prevalence of the disease is particularly high with more than 500 million cases worldwide (7.5 million in France) since the emergence of the virus.\n\nA substantial proportion of patients with SARS-Cov2 infection present persistent symptoms long after the acute infection. This is independent of the degree of severity of the SARS-Cov2 infection.\n\nThese symptoms can affect the quality of life and impede the return to work. While the majority of symptoms progress favourably with outpatient care, some persist and\u002For are particularly severe, justifying expert and multidisciplinary care.\n\nThis investigation aim to create a clinical database of patients with complex and\u002For severe post-CoviD and study blood markers what could predict the disease and orientate new ways of treatment.",[231],"Post-Covid Syndrome","2024-02-26",{"date":234,"type":40},"2024-02-28",{"date":236,"type":40},"2023-04-27",{"date":238,"type":55},"2029-04",{"name":240,"class":80},"Hospices Civils de Lyon"]